Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD

N/AActive Not RecruitingNCT04932980

Berner Augenklinik80 enrolled

Overview

The currently widely established and preferred protocol for the treatment of wet age-related macular degeneration includes a loading phase of three monthly injections without interim adaptation or treatment according to disease activity, thereafter following a T\&E strategy with treatment adaptation in increments of 2-4 weeks according to disease activity. Based on pharmacological considerations regarding the vitreal half-life of the drugs, the aim of this prospective explorative study is to test whether an early extension of treatment intervals without a loading phase is an option without compromising functional outcomes. Based on a superiority of Afl compared to Ran with regard to achieving a dry retina after one year and based on studies, but in the absence of real-life experience with Bro, it seems of interest to test how far Afl and Bro are comparable in terms of their potential to extend the treatment intervals over 12 months, the time to dryness of the retina, and number of injections. Also, it is of high clinical relevance to demonstrate efficacy with longer initial treatment intervals compared to the current possibly over-treating loading-phase with three four-weekly injections.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Wet Age-related Macular Degeneration

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Active MNV secondary to nAMD, going along with clinically significant vision loss * Patients aged 50 years or older of all sexes * Presence of IRF and/or SRF and/or subretinal hyperreflective material affecting the central subfield of the study eye on OCT * signed informed consent for this study prior to the screening visit * If possible: availability of a smartphone and willingness to perform self-testing with the Alleye app (soft criteria) Exclusion Criteria: * Any other cause of macular oedema * Structural damage to the macula precluding a visual potential * Optical media opacities not allowing an accurate performance of the protocol examinations * Any intraocular surgery within three months prior to inclusion and history of any vitreoretinal surgery * Advanced diabetic retinopathy potentially requiring any treatment within six months following inclusion or history of vitreal haemorrhage * Presence of vitreoretinal traction or tractive epiretinal membrane affecting the fovea * History of IVT with anti-VEGF or corticosteroids at any time in the study eye * Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. * Significantly worse functional prognosis in the other eye or only eye * Women of childbearing potential not willing to use an effective method of contraception during treatment and until at least 3 months after the last treatment * Pregnant or lactating women * Any systemic auto-inflammatory and auto-immune disease requiring treatment * Treatment with high-dose corticosteroids (Prednisone equivalent \>5mg/day), immunosuppressive or immunomodulatory or anti-proliferative agents for any reason * Inability or contraindications to undergo the investigated intervention

Outcomes

Primary Outcomes

Number of injections given until week 52

number injections received by patient

Time frame: 52 weeks

Secondary Outcomes

Injections until week 104

number injections received by patient

Time frame: 104 weeks

Number of treatment failures

number with treatment demand of less than 6 weeks at any time point

Time frame: 52 weeks

Number of treatment failures

number with treatment demand of less than 6 weeks at any time point

Time frame: 104 weeks

Time until drying of retina

mean interval until absence of intra- and subretinal fluid

Time frame: 52 weeks

Time until drying of retina

mean interval until absence of intra- and subretinal fluid

Time frame: 104 weeks

portion of eyes without disease activity

% patients with absence of intra- and subretinal fluid

Time frame: 52 weeks

portion of eyes without disease activity

% patients with absence of intra- and subretinal fluid

Time frame: 104 weeks

eyes under treatment intervals of ≥12 weeks

portion of eyes with stable disease under treatment intervals of ≥12 weeks

Time frame: 52 weeks

eyes under treatment intervals of ≥12 weeks

portion of eyes with stable disease under treatment intervals of ≥12 weeks

Time frame: 104 weeks

Change in visual acuity

change of VA in logRAD from baseline to week 52

Time frame: 52 weeks

Change in visual acuity

change of VA in logRAD from baseline to week 104

Time frame: 104 weeks

Change in central subfield thickness (CST)

change from baseline to week 52

Time frame: 52 weeks

Change in central subfield thickness (CST)

change from baseline to week 104

Time frame: 104 weeks

Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters

change from baseline to week 52

Time frame: 52 weeks

Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters

change from baseline to week 104

Time frame: 104 weeks

Maximal treatment interval extension

mean treatment interval extension

Time frame: 52 weeks

Maximal treatment interval extension

mean treatment interval extension

Time frame: 104 weeks

Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes